# Lecanemab

Source: https://onco.cc/drugs/da-lecanemab/  
OnCo record `da-lecanemab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.

## Summary

US labeling supports starting in mild cognitive impairment or mild dementia of the Alzheimer’s type after amyloid confirmation. Infusions are typically every two weeks. MRI monitoring and an individual bleeding-risk discussion are essential. It does not restore lost function.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Leqembi
- Code: BAN2401
- Modality: mAb
- Mechanism: Amyloid-beta–directed antibody that reduces plaques.
- Approvals: US 2023: Early Alzheimer’s disease with confirmed amyloid; JP 2023: Early Alzheimer’s disease; CN 2024: Early Alzheimer’s disease; UK 2024: Licensed; funding decisions are separate from the licence; EU 2025: Authorisation pathway; national access varies; AU 2025: Regulatory review or access may lag the US label

## Sources

- FDA traditional approval: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- targets: [Amyloid-beta](https://onco.cc/targets/da-target-amyloid-beta/)
- companies: [Biogen](https://onco.cc/companies/da-biogen/), [Eisai](https://onco.cc/companies/da-eisai/)
- terms: [ARIA](https://onco.cc/terms/da-term-aria/)
- trials: [CLARITY AD](https://onco.cc/trials/da-trial-clarity-ad/)
- fronts: [Anti-amyloid treatment](https://onco.cc/fronts/da-front-anti-amyloid/)
- technologies: [Anti-amyloid antibodies](https://onco.cc/technologies/da-tech-anti-amyloid-mab/), [ApoE testing](https://onco.cc/technologies/da-tech-apoe-testing/)
- pairings: [Lecanemab with MRI monitoring](https://onco.cc/pairings/da-pair-lecanemab-mri/)
- key papers: [Lecanemab in Early Alzheimer’s Disease (CLARITY AD)](https://onco.cc/key-papers/da-paper-clarity-ad/)
- ideas: [Antibody trials that enrol mixed and comorbid disease](https://onco.cc/ideas/da-idea-inclusive-anti-amyloid-trials/)
- roadmaps: [Anti-amyloid medicines](https://onco.cc/roadmaps/da-roadmap-anti-amyloid/)

---
JSON: https://onco.cc/api/v1/entities/da-lecanemab.json